À /47
À infection. Subsequently, the biological effects of JS1/34.5
À infection on human breast cancer cells and bone marrow were established using cell proliferation and colony formation assays, and the efficiency of cell kill was evaluated. Finally, the efficiency of JS1/34.5 
/47
À can be used to purge contaminating breast cancer cells from human bone marrow in the setting of autologous hematopoietic cell transplantation.
High-dose chemotherapy is an aggressive treatment intended to completely eradicate neoplastic cells and is frequently used to offer improved relapse-free survival to high-risk patients with a spectrum of cancers, including breast cancer, germ cell tumors, neuroblastoma, and hematologic malignancies. However, high-dose chemotherapy is severely myelosuppressive and hence needs to be followed with autologous hematopoietic stem cell rescue (1 -8) . Because tumor cells are frequently seen in the peripheral blood or bone marrow of patients with advanced cancer (9 -12) , there is a risk that the patients harvested stem cells may be contaminated with disseminated tumor cells, which can directly contribute to relapse (13) . In this context, a number of ex vivo purging strategies have been developed, to more effectively reduce the tumor burden in stem cell grafts and minimize treatment-associated causes of relapse. These include ex vivo chemotherapy (14) , CD34 + (stem) cell enrichment (15) , immunotoxins (16) , immunomagnetic removal of tumor cells (17) , and the use of cytotoxic herpes simplex virus (HSV; ref. 18 ) and adenoviruses (19) . To date, the available ex vivo purging methods seem to be limiting and can compromise the functional integrity of the hematopoietic graft (20 -23) , resulting in reduced efficacy of this approach. Hence, there is a significant need for the development of new approaches to stem cell purging.
Oncolytic viruses genetically programmed to replicate within cancer cells and to directly induce toxic effects via cell lysis or apoptosis are currently being explored in the clinic. To date, only a small group of oncolytic viruses have been used clinically. These include engineered adenovirus, herpes, and vaccinia DNA viruses with tumor selectivity (and two wild-type or spontaneously arising attenuated RNA viruses with intrinsic tumor selectivity: Newcastle disease virus and reovirus; ref. 24) .
The ability to exploit the unique features of HSV type 1 renders this virus an attractive tool for cancer therapy and offers a number of significant advantages over other viral vectors. Specifically, HSV-1 infects a broad range of cell types with high efficiency and is cytolytic by nature (i.e., the replicative life cycle of the virus results in host cell destruction). Further, the well-characterized large genome of HSV-1 contains many nonessential genes that can be replaced (up to 30 kb) with multiple therapeutic transgenes. Furthermore, the virus remains episomal within the infected cells, precluding the risk of insertional mutagenesis. Additionally, many antiherpetic drugs are available as a safeguard against unfavorable replication of the virus (24) .
Attenuated, replication-competent HSV vectors that replicate in dividing cells and result in cell death with in situ viral spread are available but are generally incapable of replicating in normal tissue (25 
Materials and Methods
Cells. Human breast cancer cell lines MDA-MB-231, MDA-MB-453, MCF-7, T47D, ZR-75-1, and Cal51 were obtained from the American Type Culture Collection (Manassas, VA). HBrSV161, normal human mammary epithelial cells immortalized with SV40 T-antigen, were a generous gift from Prof. M O'Hare (Ludwig Institute, London). All cell lines were grown in DMEM supplemented with 10% FCS, 10 nmol/L glutamine, and 100 units/mL penicillin and 200 Ag/mL streptomycin. The cells were maintained in a humidified atmosphere at 37jC and 5% CO 2 .
Virus. All viruses used in this study (JS1 WT, JS1/ICP34.5 Bone marrow cell preparation. Bone marrow samples were obtained from high-risk breast cancer patients. Bone marrow samples were diluted in HBSS, layered on Ficoll-Paque Plus, and centrifuged for 30 minutes at 2,100 Â g. The mononuclear enriched cell interface was extracted, washed twice in PBS, and resuspended in red cell lysis buffer [0.155 mol/L NH 4 Cl, 10 mmol/L KHCO 3 , and 0.1 mmol/L EDTA (pH 7.4)] for 2 minutes to remove RBC. The remaining bone marrow cells were then pelleted at 1,000 Â g for 10 minutes at 4jC, washed in PBS, and counted. Bone marrow cells were cultured in Myelocult long-term culture medium (Stem Cell Technologies, London, United Kingdom) and supplemented with 20 ng/mL human granulocyte macrophage colony-stimulating factor, 10 ng/mL stem cell factor, and interleukin-3.
Purification of primary human breast tumor cells. Primary breast tumor cells were purified according to the method of Kothari et al. (27) . Briefly, fresh breast tumor tissue was cut up and digested at 37jC with type IA collagenase (1 mg/mL) in RPMI 1640 supplemented with 5% FCS and 2 mmol/L L-glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin, 50 units/mL polymixin B, and 2.5 mg/mL amphotericin B for 2 to 5 hours. Undigested tissue was removed by filtration using a 50-mm pore followed by a 28-mm pore nylon mesh. The tumor/ epithelial cells were purified using superparamagnetic, polystyrene beads (Dynal Biotech, Bromborough, United Kingdom) coated with a mouse IgG1 monoclonal antibody (Ber-EP4) specific for two (34 and 39 kDa) isoforms of the EP4 glycopolypeptide membrane antigen expressed on the cell surface of mammary epithelial cells and then cultured in breast cancer culture media consisting of DMEM/F-12 (1:1) supplemented with 5% FCS, 5 mg/mL insulin, 10 mg/mL apotransferrin, 100 Amol/L ethanolamine, 1 Ag/mL hydrocortisone, 10 ng/mL epidermal growth factor, 15 mmol/L HEPES, 2 mmol/L L-glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin, 50 units/mL polymixin B, and 2.5 mg/mL amphotericin B. Purified primary breast cancer cells were cultured for at least 48 hours before use. mock infected with serum-free DMEM. At 24, 48, and 72 hours, the cells were examined by fluorescence microscopy for green fluorescent protein (GFP) expression. Viable cells were counted on a hemocytometer using the trypan blue exclusion assay. Clonogenic assay. Granulocyte macrophage colony-forming unit assays were carried out in triplicate using Methocult, a methylcellulose medium. After infection, 1 Â 10 5 bone marrow cells were suspended in 1 mL of Methocult H4230 supplemented with 100 AL of cytokine mix [stem cell factor, granulocyte colony-stimulating factor, interleukin-3, and granulocyte macrophage colony-stimulating factor and 1.5 AL (3 units) of erythropoietin], plated onto 35-mm dishes, and incubated in a humidified atmosphere at 37jC with 5% CO 2 . The plates were scored at days 7 and 14 for myeloid colonies (granulocyte macrophage colony-forming unit) and day 14 for erythroid colonies (burst-forming unit-erythroid).
5-Chloromethylfluorescein diacetate labeling of MDA-MB-231 cells. CellTracker 5-chloromethylfluorescein diacetate (CMFDA), chloromethyl derivative of fluorescein diacetate (Molecular Probes, Leiden, the Netherlands) was used for long-term tracing of MDA-MB-231 cells. CMFDA passes freely through the cell membrane into the cytoplasm where it undergoes a glutathione S-transferase -mediated reaction producing a cell-impermeable reaction product. The cells were stained in suspension according to manufacturer's instructions. Briefly, MDA-MB-231 cells were resuspended 200 AL serum-free DMEM containing 5 Amol/L CMFDA and incubated under normal culture conditions for 30 minutes, with intermittent rocking. The cells were then resuspended in serum-free medium for 30 minutes and washed twice in PBS.
Purging cancer cells from cocultures of bone marrow and breast cancer cells. CMFDA-labeled MDA-MB-231 cells were added to freshly prepared bone marrow cells from high-risk breast cancer patient at ratios of 10%. Cocultures were then infected with JS1/34.5
À at MOI 0.1 as described above. At 0, 3, and 6 days after infection, samples were harvested for data acquisition by fluorescence-activated cell sorting (FACS) analysis. Control cells were mock infected with serumfree DMEM. FACS analysis. MDA-MB-231 cells were labeled with CellTracker green CMFDA as above. Dead cells were identified by the addition of 50 nmol/L TO-PRO-3 (Molecular Probes) immediately before analysis. Samples were analyzed on a dual laser FACSCalibur (Becton Dickinson, San Jose, CA) with a blue laser (488 nm) used to excite CMFDA and a red diode laser (635 nm) used to excite TO-PRO-3. CMFDA fluorescence was detected using a 530/30 band-pass filter in front of the detector, and TO-PRO-3 fluorescence was detected with a 660/16 band-pass filter. Debris and cell aggregates were exclude based on their forward and side scatter characteristics. At least 50,000 events per sample were collected, and data were analyzed using CellQuest software (Becton Dickinson). The percentage of CMFDA and unlabeled cells that were live and dead was calculated for each sample.
Electron microscopy of MCF-7 cells. Adherent cells were grown on sterilized fibronectin-coated Thermanox coverslips (Agar Scientific Ltd., Stanstead, United Kingdom) for 24 hours. The cells were infected at f70% confluence and processed for microscopy at the indicated time points. Specifically, the cells were fixed in 3% glutaraldehyde in 0.1 mol/L cacodylate buffer for 30 minutes and post-fixed in 1% osmium tetroxide. The cells were then dehydrated through ascending concentrations (50-100%) of ethanol and embedded in Spurr's resin. The Thermanox coverslip was then removed before cutting, and ultrathin sections (60-80 nm) were stained in uranyl acetate and Reynold's À at MOIs of 0.01 (Â), 0.1 (E), and 1 (n) 24 hours after seeding. At the indicated time intervals, number of viable adherent cells was evaluated using trypan blue dye exclusion assay.The growth of the infected cells was compared with that of mock-infected control cells (x) for the duration of the assay. Points, mean time point; bars, SE. The SE at certain time points is too small to be discerned over the symbols.
lead citrate. Electron microscopy and interpretation of data were done by Dr. J. Moss (Division of Investigative Science, Imperial College).
Reverse WT at MOIs of 0.1 and 1. The clonogenic capacity of the cells was determined by evaluating granulocyte macrophage colonyforming unit and burst-forming unit-erythroid after infection. Figure 3 shows the results presented as mean colony-forming unit/burst-forming unit from the six patients expressed as a ratio relative to the mock-infected control value of 1. The data show that over a period of 14 days, the relative effects of JS1 WT, JS1/34.5 À /47 À , and JS1/34.5 À /GFP were similar. On average, an f20% decrease in the clonogenic capacity of the bone marrow cells was observed at MOI 0.1. However, statistical analysis (the paired t tests) of these results showed that these differences were not statistically significant (P > 0.05). In comparison, the clonogenic potential of the cells was more severely affected at MOI of 1. Based on these results, it was decided to use JS1/34. tumor cells were purified from fresh breast tumors using a purification protocol developed in our laboratories (27) . Because the number of purified primary tumor cells obtained from fresh breast tumor specimens are limiting, primary tumor cells purified from five specimens were pooled and infected with JS1/34.5 À /47 À /GFP at MOI 0.1 and infectivity assessed by examining GFP expression using fluorescence microscopy. The results presented in Fig. 5 show that as shown by GFP expression, nearly all the tumor cells in the field of view were infected by the virus. , and cultured in bone marrow culture medium (Myelocult) for 6 days. FACS analysis was then used to assess the effect of viral infection on both cell populations. Before purging bone marrow of breast cancer cells, we initially established that Myocult medium supplemented with cytokines did not affect proliferation of MDA-MB-231 breast cancer cells (data not shown). We also optimized the fluorescent labeling of breast cancer cells with CMFDA and found a concentration of 5 Amol/L CMFDA to be optimal over a period of 6 days, separating the breast cancer cells from the background autofluorescence emitted by bone marrow cells. Furthermore, concentrations of CMFDA ranging from 0.5 to 20 mmol/L did not seem to affect the growth rate of breast cancer cells (data not shown).
Efficiency of detection of CMFDA-labeled cells by FACS. In the clinical setting, the proportion of breast cancer cells in a bone marrow/peripheral blood progenitor cell graft is likely to be considerably <1% (28, 29) . To determine the efficiency of detection of small numbers of fluorescent cells by FACS, known numbers of CMFDA-labeled MDA-MB-231 cells were mixed with a population of unlabeled MDA-MB-231 cells, and the proportion of fluorescent cells was estimated over a period of 5 days. The results shown in Fig. 7 show that using FACS analysis accurately and consistently detected as few as 1% labeled MDA-MB-231 cells against a background of 99% unlabeled cells.
Evaluation Fig. 8 show that the number of live bone marrow cells was maintained throughout the 6-day period, with the percentage of dead bone marrow cells remaining at under 20%, with no significant difference between the mock-infected control and the virus-infected samples. Three additional patient bone marrow samples were also tested with similar results (data not shown). In contrast, the percentage of PI-positive dead, for MDA-MB-231 cells, increased from 10% to 90% in the viral infected cultures with a corresponding decrease in the number of viable cells. In the mock-infected control, however, the percentage of dead MDA-MB-231 cells remained at 10%, whereas the live cells continued to proliferate. These results further substantiate the above data 
/47
À at MOI 1were observed by electron microscopy at the indicated time points after infection. The control mock-infected cells exhibit centrally located nucleosome ( ) and cytokeratin filaments ( ). Twenty-four hours after infection, the absence of cytokeratin filaments is notable.Viral particles without envelopes ( ) are seen in the nucleus. Additionally, viral particles with ( ) as well as without envelope are seen in the cytoplasm, whereas viral particles with envelope are observed in the extracellular space, indicating that the envelope layer is acquired between the nuclear and cytoplasmic membrane. (Fig. 3) . The results presented in Fig. 9 show that over the period of 
À on CK19 mRNA levels in bone marrow samples from breast cancer patient. The ability to evaluate the presence of occult metastatic cells in bone marrow of breast cancer patients has been hampered by the fact that disseminated tumor cells are predominantly found in low numbers (28, 29) . Improvements in the detection rates of disseminated tumor cells have been achieved by RT-PCR (29 -32) and realtime PCR (33) for the tumor marker CK19, which is highly expressed in breast cancer cells.
To assess the ability of JS1/34.5 comparison with mock-infected controls. Comparison of relative levels of CK19 mRNA in infected and mock-infected samples at day 6 did reveal some significant differences. Specifically, 8 of the 15 samples tested showed a relative reduction in CK19 mRNA levels in infected samples compared with parallel mock-infected controls. The percentage reduction observed ranged from 42% to as much as 95% (Fig. 10) . Hence, we conclude that the reduction in relative levels of CK19 observed in Fig. 10 strongly suggest that the tumor cells were purged from the patient samples.
Recently, concerns about the specificity of detection of CK19 expression by RT-PCR (34 -37) and real-time PCR (33) 
Discussion
Autologous stem cell transplantation is used to rescue cancer patients from myelosupression caused by high-dose, multiagent chemotherapy. However, the possible presence of occult tumor cells in autologous bone marrow or peripheral blood progenitor cell transplants remains a great concern in cancer therapy (38 -40) . Although the clinical value of purging in autologous bone marrow transplants remains somewhat controversial, the development of novel tools to obtain bone marrow/peripheral blood progenitor cell preparations free of cancer cells remains a desirable objective.
Using an oncolytic HSV virus, we have previously shown enhanced tumor kill in mouse models (26) . In this study, we have examined the biological effects of a novel recombinant HSV-1 vector (JS1/34. (28, 29) .
In an attempt to more closely mimic the clinical situation, real-time RT-PCR was employed for the detection of CK19 mRNA in clinical samples of bone marrow/peripheral blood progenitor cell from breast cancer patients. This showed a significant (up to 95%) decrease in CK19 mRNA levels following treatment with JS1/34.5 À /47 À . Our results, therefore,
show for the first time that occult breast cancer cells can be potentially purged from patient bone marrow samples. Oncolytic viruses genetically engineered to replicate within tumor cells and directly induce toxic effects via cell lysis or apoptosis are currently being explored in the clinic (43) . Over the last 9 years, oncolytic viruses from five different species have been taken to phase I and II clinical trials with >300 cancer patients (24) . Although the therapeutic efficacy of oncolytic viruses as a standard agent in treatment of cancers remains to be substantiated, DNA viruses engineered to achieve tumor selectivity have been proven safe over a wide range of doses. In this context, to date, oncolytic HSV vectors have exhibited an excellent safety profile both preclinically and clinically (44) .
The concept of minimal residual disease being a favorable prognostic indicator for malignancies is widely accepted (11, 45) . Moreover, minimal tumor burden may enhance the effectiveness of immunotherapy strategies. The work described here is an improvement on the previously reported use of oncolytic HSV (16) , in that the virus used in this study is a second-generation oncolytic vector with enhanced tumor cell killing capacity compared with earlier viral vectors. Additionally, this study shows effective virus induced kill in a broader range of breast cancer cell lines than previously reported. Furthermore, the virus was found effective at reducing CK19 mRNA levels in 53% of bone marrow samples from breast cancer patients, suggesting that with suitable further development, this virus may be of use in purging of breast cancer cell in the clinical setting. With such a development, more effective purging strategies may become an integral part of novel therapies for a spectrum of malignancies in the future. À MOI 0.1 ex vivo. Expression of CK19 mRNA was examined by real-time RT-PCR 6 days after infection, and the results were normalized against GAPDH. CK19 mRNA levels were then expressed as percentage reduction in transcript number relative to the mock-infected controls for each sample.
